Skip to main content
main-content

Vasculitis

Medications

13-06-2019 | Giant cell arteritis | EULAR 2019 | News

Further support for tocilizumab use in giant cell arteritis

More than a third of patients with giant cell arteritis remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years, suggest follow-up results from the GiACTA trial.

14-03-2019 | Kawasaki disease | News

IVIG–ciclosporin combination may improve coronary artery outcomes in Kawasaki disease

Findings from the KAICA trial suggest that adding ciclosporin to intravenous immunoglobulin treatment may reduce the risk for coronary artery abnormalities among patients with Kawasaki disease.

04-02-2019 | ANCA-associated vasculitis | News

Add-on belimumab does not reduce relapse risk in ANCA-associated vasculitis

The addition of belimumab to maintenance therapy with azathioprine and low-dose glucocorticoids does not improve maintenance of remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, findings from the BREVAS trial suggest.

15-01-2019 | ANCA-associated vasculitis | News

Randomized data back EULAR guidelines for mycophenolate mofetil use in AAV

Mycophenolate mofetil is noninferior to cyclophosphamide for inducing remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, randomized trial data show.

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

27-09-2018 | Small-vessel vasculitis | Article

Treatment of urticarial vasculitis: A systematic review

Kolkhir P et al. J Allergy Clin Immunol 2018. doi: 10.1016/j.jaci.2018.09.007

B cell therapy in ANCA-associated vasculitis: Current and emerging treatment options

In this review, the theoretical background for use of dual B cell-targeted immunotherapy in anti-neutrophil cytoplasmic antibody-associated vasculitis is presented and discussed [read more].
McClure M et al. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0065-x

14-08-2018 | ANCA-associated vasculitis | Review | Article

B cell therapy in ANCA-associated vasculitis: Current and emerging treatment options

McClure M et al. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0065-x

The ongoing evolution of remission maintenance strategies for granulomatosis with polyangiitis

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients [read more].

20-07-2018 | Granulomatosis with polyangiitis | Editorial | Article

The ongoing evolution of remission maintenance strategies for granulomatosis with polyangiitis

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients.

13-07-2018 | Giant cell arteritis | News

Prolonged tocilizumab treatment needed to suppress GCA inflammation

An analysis of inflammatory markers suggests that patients with giant cell arteritis who are treated with tocilizumab still have subclinical disease activity during early remission, but not after 1 year of treatment.

12-07-2018 | Takayasu arteritis | Case report | Article

Evolution into Takayasu arteritis in a patient presenting with acute pulmonary edema due to severe aortic regurgitation: A case report

The authors report a young female who presented with acute pulmonary edema due to aortic regurgitation without any other clinical features of Takayasu arteritis, subsequently diagnosed as Takayasu arteritis after a long follow up period.

de Silva NL et al. BMC Rheumatol 2018; 2: 20. doi: 10.1186/s41927-018-0028-5

12-07-2018 | Takayasu arteritis | Article

Certolizumab pegol in the treatment of Takayasu arteritis

Novikov P et al. Rheumatology (Oxford) 2018. doi: 10.1093/rheumatology/key197

05-07-2018 | ANCA-associated vasculitis | News

Trimethoprim–sulfamethoxazole reduces severe infections following rituximab for vasculitis

A study looking at risk factors for the development of severe infections in patients with antineutrophil cytoplasm antibody-associated vasculitis following rituximab has found that trimethoprim–sulfamethoxazole prophylaxis may be of benefit.

03-07-2018 | Vasculitis | Article

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: A retrospective observational study

Bae S, Charles-Schoeman C. Clin Rheumatol 2018; 37: 2113–2123. doi: 10.1007/s10067-018-4174-3

02-07-2018 | Vasculitis | Case report | Article

A case report of REM sleep behavior disorder, Behcet’s disease, Sjogren’s syndrome and cognitive dysfunction

The authors report a patient with a history of Behcet’s disease and Sjogren’s syndrome in which rapid eye movement sleep behavior disorder was detected by polysomnographic monitoring.

Xiao F et al. BMC Rheumatol 2018; 2: 19. doi: 10.1186/s41927-018-0022-y

28-06-2018 | Giant cell arteritis | Article

Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis

Gloor AD et al. Rheumatology (Oxford) 2018: key158. doi: 10.1093/rheumatology/key158

21-06-2018 | Pathogenesis | Review | Article

The role of neutrophil extracellular traps in rheumatic diseases

Apel F, Zychlinsky A, Kenny EF. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0039-z

Image Credits